Pierre Meynet

Pierre Meynet

Auto-generated profile, based on publicly available information

Pierre Meynet

Division of Cardiology, Cardiovascular and Thoracic Department, Città della Salute e della Scienza Hospital, Turin, Italy; Department of Medical Sciences, University of Turin, Turin, Italy

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2023 in Sensors
Verified
Journal Article
Open access
PDF file
Eros PaseroEros Pasero
Eros Pasero
FGFiorenzo Gaita
Fiorenzo Gaita
VRVincenzo Randazzo
Vincenzo Randazzo
PMPierre Meynet
Pierre Meynet
SCSergio Cannata
Sergio Cannata
CGCarla Giustetto
Carla Giustetto
Short QT syndrome (SQTS) is an inherited cardiac ion-channel disease related to an increased risk of sudden cardiac death (SCD) in young and otherwise healthy individuals. SCD is often the first clinical presentation in patients with SQTS. However, arrhythmia risk stratification is presently unsatisfactory in asymptomatic patients. In this context, artificial intelligence-based electrocardiogram (ECG) analysis has never been applied to refine risk stratification in patients with SQTS. The purpose of this study was to analyze ECGs from SQTS patients with the aid of different AI algorithms to evaluate their ability to discriminate between subjects with and without documented life-threatening arrhythmic events. The study group included 104 SQTS patients, 37 of whom had a documented major arrhythmic event at presentation and/or during follow-up. Thirteen ECG features were measured independently by three expert cardiologists; then, the dataset was randomly divided into three subsets (training, validation, and testing). Five shallow neural networks were trained, validated, and tested to predict subject-specific class (non-event/event) using different subsets of ECG features. Additionally, several deep learning and machine learning algorithms, such as Vision Transformer, Swin Transformer, MobileNetV3, EfficientNetV2, ConvNextTiny, Capsule Networks, and logistic regression were trained, validated, and tested directly on the scanned ECG images, without any manual feature extraction. Furthermore, a shallow neural network, a 1-D transformer classifier, and a 1-D CNN were trained, validated, and tested on ECG signals extracted from the aforementioned scanned images. Classification metrics were evaluated by means of sensitivity, specificity, positive and negative predictive values, accuracy, and area under the curve. Results prove that artificial intelligence can help clinicians in better stratifying risk of arrhythmia in patients with SQTS. In particular, shallow neural networks’ processing features showed the best performance in identifying patients that will not suffer from a potentially lethal event. This could pave the way for refined ECG-based risk stratification in this group of patients, potentially helping in saving the lives of young and otherwise healthy individuals.

26 February 2026 in Reviews in Cardiovascular Medicine
Verified
Journal Article
Open access
PDF file
FGFederico Giacobbe
Federico Giacobbe
PMPierre Meynet
Pierre Meynet
MBMarco Balducci
Marco Balducci
SCSergio Capoccia
Sergio Capoccia
RCRino Andrea Cimino
Rino Andrea Cimino
GFGaetano Maria De Ferrari
Gaetano Maria De Ferrari
Coronary microvascular dysfunction (CMD) is a key driver of ischemia and prognosis across several non-ischemic cardiomyopathies. This review summarizes the main tools for diagnosing microvascular dysfunction and available evidence on CMD incidence and the prognostic role in patients with cardiomyopathies. In dilated cardiomyopathy, CMD is associated with reduced myocardial blood flow, greater fibrosis, adverse remodeling, and worse outcomes. In hypertrophic cardiomyopathy, CMD is highly prevalent and multifactorial (arteriolar remodeling, reduced capillary density, extravascular compression, diastolic dysfunction, and/or left ventricular (LV) outflow obstruction), correlating with fibrosis, heart failure, and arrhythmias/sudden death. In Takotsubo syndrome, CMD appears acute and reversible, with microvascular spasms as a predominant mechanism and plausible pathophysiologic basis of the event. In arrhythmogenic right ventricular cardiomyopathy, preliminary data show a blunted hyperemic response and autonomic abnormalities that may impair microvascular vasodilation. In infiltrative and storage diseases (amyloidosis and Anderson–Fabry disease), CMD is often early, preceding hypertrophy/fibrosis, and contributes to symptoms, contractile dysfunction, and adverse outcomes; in sarcoidosis, microvascular inflammation reduces coronary flow reserve (CFR) and is associated with events. Targeted therapies remain limited; optimization of risk factors and drugs that modulate endothelial/metabolic function (statins, angiotensin converting enzyme (ACE) inhibitors, vasodilating β-blockers, calcium channel blockers, sodium glucose cotransporter 2 (SGLT2) inhibitors) yielded variable signals; device-based and nonpharmacologic strategies are under investigation. In conclusion, integrating microcirculatory assessment improves risk stratification and may furnish future therapeutic targets across cardiomyopathies.

14 November 2024 in European Journal of Clinical Investigation
Verified
Journal Article
Open access
PMPierre Meynet
Pierre Meynet
RIRiccardo Improta
Riccardo Improta
MCMaria Luisa Carbone
Maria Luisa Carbone
MPMartina Pecoraro
Martina Pecoraro
IPIlaria Pagliassotto
Ilaria Pagliassotto
OFOvidio De Filippo
Ovidio De Filippo
Background: The role of sex in choosing between coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI) for unprotected left main coronary artery (ULMCA) disease has gained interest.Methods: Randomized controlled trials and adjusted observational studies comparing PCI versus CABG in ULMCA patients with outcomes by sex were included. The primary endpoint was major adverse cardiovascular events (MACE), with secondary endpoints being all‐cause mortality and repeated revascularization.Results: Ten studies (3 randomized, 7 observational) involving 22,141 ULMCA disease patients (13,411 PCI, 8730 CABG) with a median 5‐year follow‐up were included. Among males, PCI was associated with a higher risk of MACE (HR 1.18, 95% CI 1.01–1.38), while no significant difference was seen in females. However, moderator analysis showed no significant interaction between sex and revascularization strategy for MACE (p for interaction .422). No differences in all‐cause mortality were observed between PCI and CABG for either sex. Repeated revascularization risk was significantly higher with PCI for both sexes (HR 3.51, 95% CI 2.21–5.59 in males and HR 4.20, 95% CI 2.57–6.87 in females).Conclusions: In males with ULMCA disease, CABG was associated with a lower risk of MACE compared to PCI, while no significant differences were seen in females. The lack of a significant interaction between sex and revascularization strategy suggests that these findings may not reflect true sex‐based effect modification. PCI was linked to a higher risk of repeated revascularization in both sexes compared to CABG.Trial registration: The protocol was registered in the PROSPERO International Prospective Register of Systematic Reviews (ID: CRD42024537726).

6 October 2026 in Journal of the American Heart Association
Verified
Journal Article
Open access
FGFederico Giacobbe
Federico Giacobbe
FBFrancesco Bruno
Francesco Bruno
MBMarco Brero
Marco Brero
PMPierre Meynet
Pierre Meynet
ASAndrea Solano
Andrea Solano
OFOvidio De Filippo
Ovidio De Filippo
Background: Despite continuous advancements in devices and techniques, transcatheter aortic valve implantation remains associated with complications impacting outcomes. In 2021, the Valve Academic Research Consortium (VARC) introduced the VARC‐3 criteria to better classify procedural complications. Methods: We conducted a systematic review and meta‐analysis of studies reporting transcatheter aortic valve implantation‐related complications using VARC‐3 definitions between 2021 and 2025. The primary end point was all‐cause mortality at latest follow‐up. Secondary end points included major VARC‐3 complications and predictors of adverse events. Results: A total of 57 studies with 73 588 patients were included. The cohort had a mean age of 81.7 years, 51.7% were women, and most had preserved ejection fraction (55.5%) and low‐to‐moderate surgical risk (Society of Thoracic Surgeons [STS] predicted risk of mortality [PROM] 4.1%). Technical and 30‐day device success rates were 95% and 90%, respectively; early safety rate at 30 days was 66%. At average 12 months follow‐up, all‐cause mortality was 10.2%. The most common complication was permanent pacemaker implantation (13%), followed by type 2 or greater bleeding (9.7%), acute kidney injury stage 3–4 (4.7%), major vascular events (4.3%), and stroke (3.0%). Moderate/severe paravalvular regurgitation and patient‐prosthesis mismatch occurred in 4% and 8%, respectively. Study‐level pooled predictor analyses showed that acute kidney injury, type 2 or greater bleeding, paravalvular regurgitation, non‐structural valve dysfunction, and higher STS score were associated with higher mortality, while eccentric/severe aortic valve calcification was associated with significant paravalvular regurgitation. Conclusions: Transcatheter aortic valve implantation shows high procedural success but non‐negligible complication rates under VARC‐3 criteria. acute kidney injury, type 2 or greater bleeding, NSVD, periprocedural stroke and myocardial infarction after transcatheter aortic valve implantation were associated with higher mortality.

26 February 2026 in American Journal of Preventive Cardiology
Verified
Journal Article
Open access
OFOvidio De Filippo
Ovidio De Filippo
FCFrancesco Codicè
Francesco Codicè
ATAlessandro Tavelli
Alessandro Tavelli
TSTiziana Sanavia
Tiziana Sanavia
FSFlavio Sartori
Flavio Sartori
Andrea CalcagnoAndrea Calcagno
Andrea Calcagno

24 October 2026 in JACC: Case Reports
Verified
Journal Article
Open access
PMPierre Meynet
Pierre Meynet
VMValeria Mossetti
Valeria Mossetti
FGFrancesco Guerrera
Francesco Guerrera
EREnrico Ruffini
Enrico Ruffini
ACAlessia Cerrina
Alessia Cerrina
FGFulvio Gabbarini
Fulvio Gabbarini
Congenital long QT syndrome (LQTS) with neonatal onset carries a high risk of drug-refractory ventricular arrhythmias. Continuous percutaneous left stellate ganglion block (PLSGB) as a bridge to left cardiac sympathetic denervation (LCSD) is unexplored in neonates. We present a newborn female with in utero onset LQTS, complicated by functional 2:1 atrioventricular block and torsades de pointes (TdP). Despite pacemaker implantation, propranolol, and mexiletine, TdP recurred. At 25 days of life, continuous PLSGB with ropivacaine suppressed TdP. At 4 months, video-assisted thoracoscopic surgery (VATS)-LCSD was performed, with no ventricular arrhythmia recurrence in 24 months. First reported case of continuous PLSGB in a neonate with LQTS; among the few VATS-LCSD cases under 1 year. Early sympathetic neuromodulation should be considered in high-risk pediatric LQTS when medical therapy fails, as a bridge to LCSD. VATS-LCSD is feasible and safe even under 1 year.